Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Novavax Inc (NVAX) Price & Performance

Direxion Daily CSI China Internet Bull 2X SharesTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily CSI China Internet Bull 2X Shares vs Novavax Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.79 (market cap $173.62M), while Novavax Inc trades at $12.5 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 10.5× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Novavax Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Novavax Inc for 59 Days on average.

CWEBNVAX
Market Cap
$173.62M$1.82B
Volume
551,7266,198,505
Sector
Leveraged / InverseHealth
52-Week High
$55.62$12.56
52-Week Low
$17.39$6.22
Typical Hold Time
24 Days59 Days
Enterprise Value
—$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily CSI China Internet Bull 2X Shares

CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.

The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CWEB
100% Buy0% Sell
Avg holding period · 24 Days
NVAX
59% Buy41% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Direxion Daily CSI China Internet Bull 2X Shares

CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.

Read more on CWEB →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →